New study suggest that people with axSpA may benefit from cardiorespiratory training — but many don’t know what it is or what to do.
Researchers suggest that these drugs could lower risk of developing Alzheimer’s disease in people with ankylosing spondylitis.
The U.S. Food and Drug Administration (FDA) approved a new drug, upadacitinib (Rinvoq), for people with ankylosing spondylitis (AS), making it the second JAK inhibitor approved for AS.
Patients with lower disease activity had less disease progression over time, which shows the importance of finding and remaining on an effective axSpA treatment.
It’s not easy or straightforward to discover you have ankylosing spondylitis, so why would patients stop seeing the doctor after learning their diagnosis? A new CreakyJoints survey sheds some light on this complex issue.
Getting an ankylosing spondylitis diagnosis can be a challenging process that takes years — so why would anyone stop seeing the doctor after finally learning they have AS? The reasons are complex and important to understand, so that doctors and patients can improve communication and help those with AS get the care they need.
Having traditional heart disease risk factors — such as obesity, smoking, and type 2 diabetes — may be linked with having higher axSpA disease activity, according to new research.
A new study found that a screening process involving both rheumatologists and primary care physicians may reduce the delay in axial spondyloarthritis diagnosis.
New research shows that biologic medications can slow the progression of sacroiliac joint damage in axial spondyloarthritis (axSpA) patients, but it can take more than two years to see the benefits.
A new study from the ArthritisPower research registry found that more than 60 percent of axial spondyloarthritis (axSpA) patients on biologics said their treatment wore off before the next dose, which negatively impacted their disease activity and sleep.
While many studies have shown these medications help treat AS symptoms, more research has been needed about their impact on long-term disease progression.
Already approved for rheumatoid arthritis, upadacitinib may help other inflammatory conditions as well.
This is an important finding for people to know, considering that NSAIDs are a first-line treatment for AS.
More medication options and updated research about medication effectiveness has led to an update in AS treatment guidelines from the American College of Rheumatology.
Taltz inhibits an immune system protein called IL-17 that can lead to inflammation.
Almost half of patients who start a TNF inhibitor biologic are not on the same treatment a few years later.
A new study found that AS patients on anti-TNF drugs had fewer doctor and ER visits and didn’t skip work as often.
Learn more about what can happen to your chances of being in remission when you stop taking a biologic drug.
New research further confirms that patients with AS have options when it comes to picking the best treatment for them.
There's no clear evidence that drugs like DMARDs and/or TNF inhibitors make people ankylosing spondylitis more likely to be hospitalized from infection.